Assenagon Asset Management S.A. Buys 97,887 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Assenagon Asset Management increased its Zimmer Biomet stake by 1,967.6% in the second quarter, purchasing 97,887 additional shares and bringing its holdings to 102,862 shares valued at approximately $8.9 million.
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 in adjusted EPS and $2.18 billion in revenue, with revenue up 4.8% year over year. The company maintained fiscal 2026 EPS guidance of $8.47–$8.59.
• Analysts remain broadly neutral, with a consensus “Hold” rating and a $104.42 price target. Shares opened at $97.12, while Zimmer Biomet also supports a quarterly dividend of $0.24 per share, yielding about 1.0% annually.

Assenagon Asset Management S.A. boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 1,967.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,862 shares of the medical equipment provider's stock after purchasing an additional 97,887 shares during the quarter. Assenagon Asset Management S.A. owned about 0.05% of Zimmer Biomet worth $8,855,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of ZBH. 180 Wealth Advisors LLC increased its stake in Zimmer Biomet by 8.2% in the second quarter. 180 Wealth Advisors LLC now owns 2,712 shares of the medical equipment provider's stock valued at $234,000 after acquiring an additional 206 shares during the last quarter. GAMMA Investing LLC lifted its stake in Zimmer Biomet by 62.2% during the second quarter. GAMMA Investing LLC now owns 3,605 shares of the medical equipment provider's stock worth $310,000 after purchasing an additional 1,382 shares during the last quarter. CX Institutional boosted its holdings in shares of Zimmer Biomet by 155.5% in the 2nd quarter. CX Institutional now owns 2,999 shares of the medical equipment provider's stock worth $258,000 after purchasing an additional 1,825 shares in the last quarter. Hamilton Wealth LLC purchased a new stake in Zimmer Biomet in the first quarter worth approximately $226,000. Finally, Pacer Advisors Inc. grew its holdings in shares of Zimmer Biomet by 6.3% during the 1st quarter. Pacer Advisors Inc. now owns 741,594 shares of the medical equipment provider's stock valued at $67,055,000 after purchasing an additional 43,841 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZBH has been the subject of several analyst reports. JPMorgan Chase & Co. dropped their target price on Zimmer Biomet from $100.00 to $95.00 and set a "neutral" rating for the company in a report on Wednesday, April 29th. Royal Bank Of Canada lifted their price target on Zimmer Biomet from $101.00 to $110.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. Sanford C. Bernstein boosted their price objective on Zimmer Biomet from $91.00 to $93.00 and gave the company a "market perform" rating in a research report on Thursday, August 6th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Finally, Canaccord Genuity Group raised their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $104.42.

Zimmer Biomet Trading Down 0.7%

ZBH opened at $97.12 on Wednesday. The business has a 50 day simple moving average of $90.74 and a two-hundred day simple moving average of $90.31. The firm has a market capitalization of $18.53 billion, a price-to-earnings ratio of 23.63, a PEG ratio of 3.11 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts' consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period last year, the company earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet's payout ratio is presently 23.36%.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the business's stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.28% of the company's stock.

Zimmer Biomet Profile

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source